Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 10/29 11:55:00 am
425.4 DKK   +0.93%
10/27NOVO NORDISK A/S : quaterly earnings release
10/26NOVO NORDISK A/S : – Share repurchase programme
AQ
10/16NOVO NORDISK : Buy rating from Goldman Sachs
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 406.75 DKK
Weaknesses
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • Based on current prices, the company has particularly high valuation levels.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
NOVO NORDISK A/S9.01%154 697
JOHNSON & JOHNSON-5.15%364 239
ROCHE HOLDING AG-6.18%276 926
PFIZER INC.-9.52%196 991
MERCK & CO., INC.-16.24%192 678
NOVARTIS AG-21.82%179 655
ABBVIE INC.-9.09%142 051
ASTRAZENECA PLC3.59%134 249
BRISTOL-MYERS SQUIBB COMPAN..-10.02%130 187
AMGEN INC.-10.24%126 732
ELI LILLY AND COMPANY-0.09%119 029
SANOFI-11.81%116 746
GLAXOSMITHKLINE PLC-25.58%85 559
JIANGSU HENGRUI MEDICINE CO..24.83%71 749
CHUGAI PHARMACEUTICAL CO., ..22.77%65 426
ALLERGAN PLC0.97%63 659
More Results
Financials
Sales 2020 128 B 20 043 M 20 043 M
Net income 2020 42 262 M 6 626 M 6 626 M
Net cash 2020 10 720 M 1 681 M 1 681 M
P/E ratio 2020 23,5x
Yield 2020 2,12%
Capitalization 988 B 155 B 155 B
EV / Sales 2020 7,64x
EV / Sales 2021 7,16x
Nbr of Employees 43 526
Free-Float 75,1%
Upcoming event on NOVO NORDISK A/S
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes